

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[About Us](#)  
[Sloan Kettering Institute](#)

IMMUNOLOGY PROGRAM

Search

# The Michael Glickman Lab

[Research](#)



[Education & Training](#)

What can we help you find today?  
**Research**

[News & Events](#)  
Search



Michael S. Glickman, MD


---

We are broadly interested in the biology of mycobacteria, including the major human pathogen *M. tuberculosis*, the nonpathogenic model organism *M. smegmatis*, and the cancer biotherapeutic agent BCG.

[View Lab Overview \(https://www.mskcc.org/research/ski/labs/michael-glickman/overview\)](https://www.mskcc.org/research/ski/labs/michael-glickman/overview)

## Research Projects

- [Molecular Pathogenesis of \*M. tuberculosis\* infection](#)
- [DNA Repair and Mutagenesis in Mycobacteria](#)
- [Mechanisms of BCG induced anti-tumor immunity](#)



## Featured News



### [MSK Scientists Solve One of TB's Deadliest Tricks](#)

Scientists at Memorial Sloan Kettering have pieced together the biochemical mechanism by which the tuberculosis bacterium sneaks past our immune defenses.



## [The ABCs of BCG: Oldest Approved Immunotherapy Gets New Explanation](#)

BCG has been used to treat bladder cancer for more than 30 years. Scientists are still learning how it works.

## Publications Highlights

[Distinctive roles of translesion polymerases DinB1 and DnaE2 in diversification of the mycobacterial genome through substitution and frameshift mutagenesis](#) , P Dupuy, S Ghosh, O Adefisayo, J Buglino, S Shuman, MS Glickman, Nature Communications 13 (1), 4493

---

[Roles for mycobacterial DinB2 in frameshift and substitution mutagenesis](#) , P Dupuy, S Ghosh, A Fay, O Adefisayo, R Gupta, S Shuman, ...Elife 12, e83094

[View All Publications](#)

## People

## Michael S. Glickman, MD

- Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including the use of mycobacteria as bacterial cancer therapies.
- MD, Columbia University College of Physicians and Surgeons

 [glickmam@mskcc.org](mailto:glickmam@mskcc.org)  
Email Address

 [646-888-2368](tel:646-888-2368)  
Office Phone

 [View physician profile](#)  
Physician profile

### Members



Michael Glickman  
Member; Alfred P. Sloan Chair



John Buglino  
Senior Research Scientist



Allison Fay  
Senior Research Scientist

Lab

Alumni

Lab Affiliations

**Open**


### Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit



Gil Redelman-Sidi  
Assistant Attending Physician



Emilee Barnard  
Graduate Student

[Resources for Postdocs](#)

## Get in Touch



[glickmam@mskcc.org](mailto:glickmam@mskcc.org)

Lab Head Email



Jamie Bean  
Assistant Lab Member, EIO Cell  
Bank director



Anna Benjamin  
Lab Manager



M. Maria Elgrail  
Postdoctoral Research  
Associate

 [646-888-2368](tel:646-888-2368)

Office Phone

 [646-422-0502](tel:646-422-0502)


Office Fax

 [646-888-2360](tel:646-888-2360)


Lab Phone

 [646-422-0502](tel:646-422-0502)


Lab Fax



Shireen Khayat  
Graduate Student



Yaprak Ozakman  
Research Scholar



Veronica Shields  
Administrative Assistant

[Michael Glickman's Bluesky](#)

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other

organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Michael S. Glickman discloses the following relationships and financial interests:

- Burroughs Wellcome Fund  
Professional Services and Activities
- EpiStemmyx, Inc.  
Equity; Professional Services and Activities (Uncompensated)
- IRB Barcelona  
Professional Services and Activities
- Vedanta  
Equity; Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center